Thank you for standing by and welcome to the STAAR Surgical 4Q '19 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Brian Moore, Senior Director, Investor, Media Relations and Corporate Development. Thank you. Please go ahead.

Thank you, Jessie, and good afternoon everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to review the Company's financial results for the fourth quarter and fiscal year ended January 3, 2020. On the call today are Caren Mason, President and CEO and Deborah Andrews, Chief Financial Officer. The press release of our fourth quarter results was issued just after 4:00 PM Eastern Time and is now available on STAAR's website at www.staar.com. Before we begin, let me quickly remind you that during the course of this conference call, the Company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the Company's projections, expectations, plans, beliefs, and prospects. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release as well as STAAR's public periodic other filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales in constant currency. We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in today's press release. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit themselves to two initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperation with this process. Now, I'd like to turn the call over to Caren Mason, President and CEO of STAAR.

Thank you, Brian, and good afternoon everyone. The fourth quarter results we reported today are consistent with the preliminary results we issued on January 13 and represent continued financial, operational, and market share momentum for STAAR. ICL sales, ICL units, gross margin, cash, and earnings per share, all grew significantly over prior-year results. STAAR achieved 33% ICL unit growth in 2019, successfully hurdling breakout levels of growth in calendar year 2018. Global ICL units grew 27% in the fourth quarter. Q4 represented the 10th consecutive quarter of double-digit ICL sales and unit growth as our lenses continued to take share of the refractive market. Our EVO ICL family of lenses is growing at rates significantly above the low-to-mid single digits of many of our industry peers and we believe this demonstrates the growing reality that the future of refractive vision correction will be lens-based. The time for STAAR is now. On a regional basis, ICL unit growth in the fourth quarter was driven by standout performance in several markets, including Japan units up 95%, China units up 43%, Germany units up 29%, Spain units up 20%, India units of 16%, and ICL units in the US up 10% as compared to the prior-year period. Growth during the fourth quarter and fiscal 2019 was driven by increased adoption of our lens-based solution to visual freedom by new and existing surgeon customers, new marketing programs, and new and expanding strategic cooperation and alliance agreements. One example of our success in marketing during fiscal 2019 was a fourfold increase in the number of visits to our ICL website Doc Finder. We recorded more than 1 million visits to our Doc Finder in 2019. As a potential leading indicator of future ICL patients, the increasing visits to our Doc Finder illustrate that our marketing…

Thank you, Caren, and good afternoon everyone. I will start the financial overview with a summary of top line results and then provide more detail down the income statement. STAAR reported net sales of $38.9 million in the fourth quarter of 2019, an increase of 25% over the $31.2 million reported in the year-ago period. The foreign currency headwinds, primarily the euro was just $20,000 for the fourth quarter as compared to approximately $1.3 million for the full fiscal year in 2019. Strong top line growth was driven by ICL unit and revenue growth of 27%. ICL sales represented 86% of total Company sales for both the fourth quarter and fiscal year of 2019. Moving down the income statement, our gross profit margin for the fourth quarter was 74.1%, up 40 basis points as compared to 73.7% in the prior-year quarter. Gross margin in the fourth quarter increased due to improved unit costs, partially offset by period costs associated with the project to resume manufacturing in Switzerland. Gross margin on our ICL product lines remains in the 80% to 85% range and we continue to anticipate total Company gross margin above 80% by the end of the three-year 2020 to 2022 planning period. Approximately half of the anticipated margin improvement to come from manufacturing cost reductions and half from continued mix shift to our higher margin ICL business. Total operating expenses for the fourth quarter were $26.5 million, an increase of 21% compared to the prior-year quarter of $21.8 million. Taking a closer look at the components of operating expenses, G&A expense in the fourth quarter was $7.9 million, compared to the prior-year quarter of $6.2 million. The increase in G&A expense was due to increased headcount and salary and related expenses, including stock-based compensation, increased travel expenses, increased insurance…

Thank you. [Operator Instructions] Your first question comes from Jason Mills with Canaccord Genuity. Your line is open.

Hi, great, thanks. Caren, can you hear me okay?

Yes, I can hear you, Jason.

Okay, great. Again, congratulations on a great year.

Thank you.

First, wanted to start with coronavirus. Thank you so much for the color. I guess the question is the $5 million to $7 million makes sense at this point given the uncertainty to us, but I guess over what time period do you expect these sales or these procedures to be done and how will you account for them. So, let's say that it's mostly felt in the first quarter and they come back perhaps over Q2, Q3 time frame. Will you be able to call that incremental revenue out -- the incremental revenue upside that you saw offset to the downside during this crisis?

Bottom line is, we had already planned contributions from each of our major markets on a quarterly basis. And as you know, it's always been split 22%, then 27%, I believe 26%, and 25%. So, what we're doing now is we're taking a look at the number of units that we didn't realize in February, and we've already actually received orders from customers to our distributor for shipment as soon as they reopen. So, we're already seeing what we call that kind of held back robust interest in getting back to work in a big way. So, in answer to your question when we -- or next on the call or when we have visibility we feel it's important to share, we'll talk about how the spread will be. My expectation based on talking to our team, and the customer is they are going to work very, very hard, very aggressively and a lot of over time to get back on track to what they had planned for their year. I just want to remind everyone that they have budgets that they need to meet. They have employees they need to pay. They are in a very, let's say, recovery mindset to get back to work and get back on their own income statements in the right way from the smallest practice to the largest hospital.

Great, that's loud and clear. My second question, let's talk clinical, Caren, if you can for second. Could you talk about the approval timing? You mentioned DEKRA is still evaluating. Is this in line with your expectations, and I guess, maybe talk a little bit about your -- more color on the planned roll-out, the phased roll-out. And then in the United States, can you give us an update on pace of enrollment. I guess is it -- it's probably sort of more yesterday than the day before, so on and so forth, but could you give us an update on how that's going? Thank you.

Sure. So our phased roll-out is designed to make sure that those who have participated with us as principal investigators, those who are familiar and very strong and excited about presbyopia through trying other product and who are already enthusiastic about bringing presbyopia deep into their practice will be the first practices where we'll roll out the product. We have a detailed plan for a one-year time frame in terms of starting off with a dozen strong sites, then moving to 25, 50, and then hundreds thereafter. We plan to do a major roll out at ESCRS on our experts meeting in the October time frame. Our earliest surgeons will have the benefit of all of the patient and surgeon materials, the training programs, everything will be ready to go. In fact, it's ready to go now. But what we want to make sure of is that as we initially roll out, the near, intermediate, and far vision characteristics and quality that our outstanding lens that is well-characterized, in daily practice which, as you know, is a learning experience for surgeons who have been involved in just a clinical trial environment. So, it's good for the surgeons and it's good for us in guiding all the new practices we plan to bring on with this lens. In terms of the pace of the US rollout, we are extremely excited about the feedback we're getting, a number of the surgeons had both -- I'm not -- my clinical people don't want me to talk. So, I think the bottom line is we have a lot of patients in the queue. I'll leave it there.

Thank you. Thank you, Caren.

You're welcome, Jason.

Your next question comes from Ryan Zimmerman with BTIG. Your line is open.

Great. Thank you. So, just a follow-up to Jason's question. Caren what impact are you assuming right now in Korea and Japan with the coronavirus...

So, we speak routinely, of course, with our teams all over the world and today is the day on a weekly basis that our sales leads call in to give up to the moment detail and I can tell you that at this point in time, Japan is operating fully normally and aggressively as they have been, no change. And Korea, there has been some concern, but what we're being told is, it's not in refractive surgeries. It's especially in cataract surgery. So at this point in time, we are not getting any negative feedback from our teams.

Okay, that's very helpful. And then just a follow-up to on the clinical side of things, you talked about some of the steps you're going to go through for the EVO clinical trial in the US. That data preparation and submission period, can you just talk about kind of what the assumed time frame would be for that and we can kind of then make our estimates or guesses around potential approval timing in the US. Thank you.

Yes, typically companies give themselves approximately three months to six months to compile the data and to do all the checks and balances associated with making sure that we present accurate and complete information to be reviewed by the regulatory body. Obviously, our goal will be to accelerate if possible, but to make sure that we are on the side of complete and effective safety and effectiveness data.

Thanks for taking the question.

Thank you. Thank you very much for initiating coverage and asking us questions today, Ryan. We appreciate it.

Your next question comes from Anthony Petrone with Jefferies. Your line is open.

Hi, thank you, and thanks for taking the question. Maybe just a follow-up on coronavirus, just trying to reconcile maybe some of the comments that Alcon made this morning on their call. They have seen a pretty significant impact in China, in February specifically, they called a 90% reduction in procedures versus their internal estimates. So, just trying to get a sense of the February trends relative to the comments that Alcon made and then I'll have a follow-up on the US clinical study. Thanks.

Sure. Thank you, Anthony. Certainly, by the end of January and into February where clinics and hospitals were closed and remain closed, no procedures were performed. In the first three weeks of January, we had an extraordinary kick off to the year and a number of procedures remain scheduled for when these clinics and hospitals reopen. So, I think the bottom line is, I think, it follows from what we've been hearing all throughout from our sales team is that it seems that the cataract lens business has been deeply impacted in terms of what occurred and what is expected in terms of a negative relative recovery, but these refractive procedures as I explained in my prepared remarks, many of them have either prepaid or already are 100% set to go. So, we are seeing a difference in the refractive response at this time. We'll see how things play out.

That's great. Maybe the follow-up just to stay on this topic for a moment, would be the idea that there is a good chance to recapture these procedures. And so, are you seeing just a rescheduling at this point because, again, on the Alcon side, they talked about possibly recapturing some, but some of those procedures potentially being lost. And then I'll have just one final one on the US study. Thanks.

Well, I can't comment on Alcon's opinion. Our outlook is that a refractive patient who has committed to all the benefits that an ICL has over other laser vision correction procedures have a really enthusiastic customer. And so, I believe the patients, the fact that there has been scheduling online by our customers, the fact that we have energized over 2,500 practitioners, 500 of tumor surgeons during this process, we are in full contact. So, we feel quite close to the situation and we're pretty confident in terms of if work gets done, it will get done with us. Thank you, Anthony.

That's pretty -- thank you.

Your next question comes from Jim Sidoti with Sidoti & Company. Your line is open.

Good afternoon. I guess, like everybody else...

Hi, Jim.

We're all focused on the coronavirus. The question I had is, how you set the capacity because if it plays out as the way you think it will, these procedures are going to be rescheduled, possibly late in Q1, but more likely Q2, Q3. Do you have the capacity to meet demand?

Absolutely. We are -- this morning again, we went through inventory both Spheric [ph] and Toric lenses, the ability to bring in Toric in the most-requested sizes for all the markets, especially China's busy season, will most likely take place at the end of Q2 and into Q3. We are very well prepared.

And then my second question is related to the US launch. Obviously, you can't market the EVO to customers until you get the approval, but are you able to start training surgeons to do the procedure before the approval and have you started?

No, no. We can do nothing on the commercial side, even if it is training related until we have approval of the EVO lens in the US. We are purely managing with our contract research organization partner, a really extraordinary clinical trial experience for the surgeons and the patient. Surgeons will share information amongst each other a little bit, but they know what the requirements are in terms of their ability to really talk about the trial.

I thank you.

Thank you, Jim.

Your next question comes from Brian Weinstein with William Blair. Your line is open.

Hi, good afternoon. This is actually Andrew Brackmann on for Brian. I'll follow the similar line of question here. So, I guess, in the context of that $5 million to $7 million just you've talked about, can you maybe just expand on how that is expected to play out with the strategic cooperation agreement strategy that you have, I guess, the reason I ask is because it's my understanding that these -- some of these agreements, sort of call for required minimum purchase levels on a quarterly basis and as we're talking about $5 million to $7 million of a delay here. I am just curious on what the stipulations are in that contracts that allow for that delay and your confidence in gaining that back. Thanks.

Okay. Well, I think it's important to remember that we have an appropriate setup with our distributor in terms of getting lenses to each of the facilities on a predetermined basis. And so, we will have the ability to meet whatever the partner really wants in terms of delivery time as well as selection of lenses. So, when you ask whether or not we would hold them to their quarterly commitment, the answer is yes, but in terms of the timing of the total for the year, there'll be flexibility and I'm sure some lenses will move from quarter to quarter, but we're not really concerned in any way that anyone's going to be using the February time frame as a reason not to meet their annual commitment. If anything, we've been assured the opposite that they cannot wait to get back and that they have no intention of missing their annual commitment.

Okay, thank you. That's very helpful. And then on the US clinical trial, just on the clinical trial website, it has estimated primary completion date as January 1, 2021. So, we take that as when the follow-up is completed or when you expect the final patient to be enrolled. Thank you?

Okay. So, the January 2021 is the end of the trial and then there is the preparation of the data to be given to the FDA on as quick a time frame as we can achieve, three months to six months.

Got it. Thank you.

You're welcome.

Your next question comes from Bruce Jackson with The Benchmark Company. Your line is open.

Hi, thank you for taking my question. I wanted to know if we could get an update on the manufacturing site build out in Switzerland.

Okay. So, we have continued the process of preparing the need outside, but are expectation is that we'll probably move back by approximately a quarter or two the shipments manufactured product from the Swiss facility and the reason for that is the time frame is not as concerning, candidly, as it was when we had what we felt was a potential trade challenge for American manufactured product. We still believe that the Swiss manufactured product is the right answer for our Asian customers, especially China, who appreciate a Swiss-manufactured label, but we are a little less in terms of intensity with getting that done and we are accelerating other spending for the near term that we believe we'll have a quicker return to the Company.

Okay, great. Thank you. And then just a follow-up on the EDOF program. When do you anticipate starting the EDOF Toric pilot study?

The EDOF Toric pilot study at this point in time will -- is scheduled definitely in 2020. We have not finalized the date, but we have everything ready to go.

Okay, super. Thank you very much.

Thank you, Bruce.

And that's all the time that we have for questions. I turn the call back to Caren Mason for any closing remarks.

I'd like to thank everyone today for their participation on our call. We'll be on the road in the coming weeks, meeting with the investment community where we look forward to speaking with and seeing many of you. As always, we appreciate your interest and investment in STAAR. All the best to all of you. Thank you.

This concludes today's conference call. You may now disconnect.